<DOC>
	<DOC>NCT01437618</DOC>
	<brief_summary>The purpose of this study is to prospectively verify if FOLFOXIRI plus bevacizumab as first-line treatment could be considered a promising approach to improve the outcome of BRAF mutant metastatic colorectal cancer patients</brief_summary>
	<brief_title>First-line FOLFOXIRI Plus Bevacizumab in BRAF Mutant Metastatic Colorectal Cancer</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<criteria>Histologically confirmed colorectal adenocarcinoma; Availability of formalinfixed paraffin embedded tumor block from primary and/or metastasis; BRAF V600E mutant status of primary colorectal cancer and/or related metastasis; Unresectable and measurable metastatic disease according to RECIST criteria; Male or female, aged &gt; 18 years and &lt; 75 years; ECOG PS &lt; 2 if aged &lt; 71 years; ECOG PS = 0 if aged 7175 years; Life expectancy of more than 3 months; Adequate haematological function: ANC ≥ 1.5 x 10^9/L; platelets ≥ 100 x 10^9/L, Hb ≥ 9 g/dL; Adequate liver function: serum bilirubin ≤ 1.5 x ULN; alkaline phosphatase and transaminases ≤ 2.5 x ULN (in case of liver metastases ≤ 5 x ULN); Serum creatinine ≤ 1.5 x ULN; Previous adjuvant chemotherapy is allowed if more than 12 months have elapsed between the end of adjuvant therapy and first relapse; At least 6 weeks from prior extended radiotherapy and 4 weeks from surgery; Written informed consent to experimental treatment and molecular analyses. Presence or history of CNS metastasis; Serious, nonhealing wound, ulcer, or bone fracture; Evidence of bleeding diathesis or coagulopathy; Uncontrolled hypertension; Clinically significant (i.e. active) cardiovascular disease for example cerebrovascular accidents (CVA) (≤6 months before treatment start), myocardial infarction (≤ 6 months before treatment start), unstable angina, NYHA ≥ grade 2 chronic heart failure (CHF), uncontrolled arrhythmia; Current or recent (within 10 days prior to study treatment start) ongoing treatment with anticoagulants for therapeutic purposes; Chronic, daily treatment with highdose aspirin (&gt;325 mg/day); Symptomatic peripheral neuropathy ≥ 2 grade NCICCTG criteria; Active uncontrolled infections; Treatment with any investigational drug within 30 days prior to enrolment; Other coexisting malignancies or malignancies diagnosed within the last 5 years with the exception of curatively treated basal and squamous cell carcinoma of the skin or in situ cancer of the cervix; Major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to study treatment start; Lack of physical integrity of the upper gastrointestinal tract or malabsorption syndrome; Fertile women (&lt; 2 years after last menstruation) and men of childbearing potential not willing to use effective means of contraception.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>September 2011</verification_date>
</DOC>